相关实验视频

Updated: Jun 9, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

MiR-497-5p通过调节LITAF促进内皮原生细胞迁移和血管生成来改善深静脉血栓形成

Shuguo Xu¹, Zhihong Yang¹, Longbiao Li¹

¹Interventional and Vascular Surgery Department, Ningde Municipal Hospital of Ningde Normal University, No.7 Jiaocheng North Road, Jiaocheng District, Ningde, 352100, Fujian, China.

Biochemical genetics

|October 21, 2024

概括

微RNA-497-5p通过向LITAF.提升内皮前代细胞功能,促进愈合并通过向LITAF.减少深静脉血栓 (DVT). 这一发现为DVT治疗提供了一个新的治疗策略.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
血栓形成研究研究

背景情况:

深静脉血栓塞 (DVT) 是心血管疾病中的一个重大全球健康挑战.
微RNAs (miRNAs) 已经成为心血管病理中的关键调节者.
需要阐明miR-497-5p在DVT病变发生中的特定作用.

研究的目的:

研究miR-497-5p对内皮原生细胞 (EPC) 功能的影响.
确定miR-497-5p和脂多糖诱导的TNF因子 (LITAF) 之间的调节关系.
为了评估miR-497-5p在DVT大鼠模型中的治疗潜力.

主要方法:

从大鼠骨髓中分离出EPC,并用miR-497-5p模仿物和/或LITAF.转移.
用CCK-8,Transwell和管形成试验来评估细胞增殖,迁移和血管生成.
在体内DVT模型是通过下腔静脉绑定建立的,通过组织学分析和血清D-二次数评估.

主要成果:

过度表达miR-497-5p显著增强了EPC的扩散,迁移和血管生成.
确定LITAF是miR-497-5p的直接标,miR-497-5p对LITAF的表达有负面调节.
过度表达LITAF逆转了miR-497-5p对EPCs的有益影响.
在体内,miR-497-5p的使用通过降低LITAF的调节,降低了血栓形成和D-二聚合物水平.

结论:

miR-497-5p促进EPC的增殖,迁移和血管生成,从而减轻DVT.
在DVT中miR-497-5p的治疗效果是通过抑制LITAF的介导.
miR-497-5p是治疗深静脉血栓的有前途的治疗标.

关键词:

血管新生的产生.深静脉血栓形成的原因是深静脉血栓.内皮前代细胞是内皮前代细胞.在LITAF中,它是最重要的.在MiR-497-5p中使用.

更多相关视频

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

A Rabbit Venous Interposition Model Mimicking Revascularization Surgery using Vein Grafts to Assess Intimal Hyperplasia under Arterial Blood Pressure

A Rabbit Venous Interposition Model Mimicking Revascularization Surgery using Vein Grafts to Assess Intimal Hyperplasia under Arterial Blood Pressure

Published on: May 15, 2020

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...